#EULAR2021 OP0138 - Radiographic AxSpA in LDA, SPACING anti-TNF vs continue care. 83% were able to ⬆️ dosing interval at month 12, drug efficacy recovered in pts with relapsed disease. Worth trying in stable patient who wants to wean down meds. @RheumNow

Do patients with #SpA have a different phenotype if they have "root joint disease"? Find out at the #EULAR2021 Poster Tour #POS0239 or at https://t.co/30JdHxTKus https://t.co/ocEefm8II9

• Root Joint Involvement in Spondyloarthritis: A Post-hoc Analysis from the Inter…

@MeralElRamahiMD @RheumNow True that axSpA is diff from pts with peripheral SpA predominantly but isn’t it circular reasoning to say axial has more HLAB27+ as that is group in whom criteria were developed including HLAB27?

Don’t forget to use imaging that you already have! CT Abd/Pelvis (ordered for nonMSK) of 301 IBD pts shows underlying sacroilitis ⭐️60/301 had sacroilitis on CT ⭐️11/60 had AxSpA ⭐️3/60 previously undiagnosed axSpA Abs#POS0035 #EULAR2021 @RheumNow

➡️ASTERA = PIII trial that showed superior efficacy of Netakimab (IL-17Ai) vs PBO in pts w/ active r-axSpA. Excluded pts prev tx w/ 2 or more TNFi ➡️OP0142 = sub-analysis showing Netak ⬇️ dz activity in AS pts irrespective of sacroillitis on MRI at b/l #EULAR2021 @Rheumnow https://t.co/faT3M0xQiR

I haven’t used it but… Netakimab (IL-17i) approved for treatment of PsO, AS, and PsA in Russia and Belarus ⭐️⬇️AS activity w/ or w/o MRI sacroilitis Abs#OP0142 #EULAR2021 @RheumNow

Bingo. It always had been rather odd to me that you would call someone nr-SpA when they had MR evidence of disease; xrays are not sensitive to pick up changes. While we're at it, can we just use the term "imaging" instead of "radiographs" with the availability of better tech? https://t.co/I6reoHyywf

• https://twitter.com/ERheumat/status/1400114084800909312

Filgotinib showed ⬇️ in spinal inflammation of AS pts after 12 weeks! ⭐️Subscores of the posterior elements, facet joints and vertebral bodies showed significant changes ⭐️no significant changes in spine fat, bone erosion or new bone formation Abs#OP0141 #EULAR2021 @RheumNow https://t.co/tcBFuxnu4n

Fatigue 35-80% of rheumatic pts! Excellent talk on fatigue in arthritis, SpA and systemic rheumatic disease! Abs#OP6875 #EULAR2021 @RheumNow How do you help pts manage fatigue?

➡️COMPLETE-AS = obs study of bDMARD-naive Canadians w/ active AS tx w/ ADA or nbDMARDS/NSAID. ➡️> overall⬇️in dz burden & shorter time to achieve therapeutic response w/ ADA. But, ADA pts had higher b/l dz OP0143 #EULAR2021 @RheumNow https://t.co/FpJmugsdVw

Efficacy & Safety of UPA after 1yr from SELECT-AXIS 1 study? ⭐️187 bDMARD-naive, active AS pts w/ inadeq resp to NSAID ⭐️82-85% txed w/ UPA 15mg QD achieved BASDAI50 or ASDAS LDA over 64w 🚫 new safety signal & ZERO VTE, MACE, TB, or deaths w/ UPA. OP0144 #EULAR2021 @RheumNow https://t.co/mFbgQjsD6f

Interesting results from our post hoc analysis of #ASAS #PerSpA presented at #EULAR2021 by Dafne Capelusnik ⭐️Individual socioeconomic factors associated with poorer outcomes ⭐️Living in low GDP country associated with higher disease activity but paradoxically lower fatigue https://t.co/2SmKZPy8mw

#EULAR2021 PROs in Spa and PSA: Dr. Rachel Tate ( @uptoTate ) Dr. Rachel Tate reviews two abstracts - OP0051 and OP0049 - presented at the virtual EULAR 2021 meeting. https://t.co/sUXTXDXrFh https://t.co/tQZktnlUXj

• https://bit.ly/3wSTLSo

RheumNow’s expanded coverage of the #EULAR2021 meeting is sponsored in part by Novartis, Bristol Myers Squibb, Janssen. All content chosen by RheumNow & its Faculty.